Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Portfolio Pulse from
Kura Oncology, Inc. has been upgraded to a Strong Buy due to its collaboration with Kyowa Kirin, which includes $330M upfront and potential $1.2B in milestone payments. Their lead candidate, Ziftomenib, shows promising results in AML treatment, potentially addressing up to 50% of patients.
December 18, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kura Oncology's stock has been upgraded to Strong Buy due to its collaboration with Kyowa Kirin, which includes significant financial benefits and promising results from its lead candidate, Ziftomenib, in AML treatment.
The collaboration with Kyowa Kirin provides immediate financial benefits and potential future payments, enhancing Kura's financial position. The promising results of Ziftomenib in AML treatment increase the likelihood of FDA approval and successful commercialization, justifying the Strong Buy rating.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100